- Home
- BRO vs MRNA Comparison
BRO vs MRNA Comparison
Compare BRO & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRO | MRNA |
|---|---|---|
| Founded | 1939 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2B | 19.7B |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | BRO | MRNA |
|---|---|---|
| Price | $65.10 | $50.96 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 15 | 12 |
| Target Price | ★ $83.53 | $34.27 |
| AVG Volume (30 Days) | 3.2M | ★ 5.3M |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.98% | N/A |
| EPS Growth | N/A | ★ 21.77 |
| EPS | ★ 3.16 | N/A |
| Revenue | $5,902,000,000.00 | ★ $19,263,000,000.00 |
| Revenue This Year | $25.82 | $8.74 |
| Revenue Next Year | $6.85 | $16.18 |
| P/E Ratio | $21.26 | ★ N/A |
| Revenue Growth | ★ 22.83 | 4.29 |
| 52 Week Low | $63.29 | $22.28 |
| 52 Week High | $121.70 | $59.55 |
Technical Indicators
Market Signals| Indicator | BRO | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.56 | 50.91 |
| Support Level | $63.29 | $47.61 |
| Resistance Level | $69.74 | $54.94 |
| Average True Range (ATR) | 2.12 | 2.53 |
| MACD | 0.30 | -0.21 |
| Stochastic Oscillator | 32.21 | 50.66 |
Price Performance
Historical ComparisonAbout BRO Brown & Brown Inc.
Brown & Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The company's business is divided into two reportable segments: (i) the Retail segment, and (ii) the Specialty Distribution segment. The Retail segment provides a broad range of insurance products and services to commercial, public and quasi-public entities, and to professional and individual customers, as well as non-insurance warranty services and products through automobile and recreational vehicle dealer services businesses. The Specialty Distribution segment consists of wholesale brokerage and specialty businesses. Its geographic area is U.S, U.K and Others.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.